
TRIALSWEST EXPANDS WITH A NEW CLINICAL TRIAL SITE

Highlights

- TrialsWest is expanding with a new clinical trial site to open north of Perth
 - Site expected to open in August and provide significant additional service capacity
 - Near term growth expected from additional patient recruitment into existing trials
 - Represents first step in the TrialsWest growth strategy of building market share within the global pharma clinical trials marketplace
 - Resonance Health recently completed the acquisition of the TrialsWest business
-

Resonance Health Limited (**Resonance** or **Company**) (ASX: RHT) is pleased to announce the expansion of its TrialsWest business with the expected August opening of a new trial site in Osborne Park, Western Australia (**Northern Site**).

Osborne Park is ideally situated ~ 8km north of the Perth CBD, and ~30km from the existing TrialsWest site located south of Perth in Spearwood (**Southern Site**). The addition of the new Northern Site doubles TrialsWest's physical site and patient capacity.

Importantly the Northern Site will form the basis of a northern suburbs' patient catchment area, with the existing Spearwood site continuing to service the southern suburbs catchment area. Collectively, the two sites will provide TrialsWest with the capacity to better service the 2.31 million people living in the Greater Perth area. Perth is now the fourth most populous city in Australia, and among the nation's fastest growing.¹

This new Northern Site is the first step in Resonance Health's expansion strategy for TrialsWest and is consistent with the aspirations communicated at the time of the TrialsWest acquisition (see ASX releases on 31 May 2023 and 2 April 2023). This strategy is focused on delivering growth over multiple years, with further new sites being targeted along with complementary acquisitions.

The new Northern Site fits neatly within TrialsWest's strategic plan of low-cost expansion (targeting already fitted out premises located in affordable densely populated suburbs) which provide convenient access to patients via good transport links and the availability of parking.

Resonance Health CEO, Mr. Andrew Harrison commented:

"We are very pleased with the integration of the TrialsWest business over the last month and the significant opportunity it represents as a platform for future growth."

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact:

¹ ["Population estimates by LGA, Significant Urban Area, Remoteness Area and electoral division, 2001 to 2022"](#). abs.gov.au. Australian Bureau of Statistics. Retrieved 26 March 2024

Andrew Harrison – Chief Executive Officer

E: andrewh@resonancehealth.com

P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis

The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US



/Resonance-Health-Ltd



/ResonanceHealth



/ResonanceHealthLtd